News | September 02, 2021
Granules India receive DRDO licence to manufacture and market 2-DG
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The company has to approach the DCGI for approval to commence the trials
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Filing for WHO Emergency Use Authorisation this month
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
